TYRA at a glance
Tyra Biosciences, Inc. (TYRA, SEC CIK 1863127) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Tyra Biosciences, Inc. (TYRA) shares worth $304.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on September 15, 2026 of 9,078,529 shares at $22.03 per share.
- In the last 90 days, TYRA insiders reported 1 open-market purchase ($20K) and 0 open-market sales ($0) on Form 4, a net purchase of $20K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$20K
- 13F holders
- 25 funds
- $304.9M · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report
- Carried-forward risks include clinical-trial, regulatory approval, commercialization, and financing uncertainties
- Continued biotechnology competition and dependence on intellectual-property protection
- Ongoing need for additional capital to support operations and development programs
Management Discussion & Analysis
- Revenue $0, unchanged YoY, clinical-stage company with no product revenue
- Net loss $51.1M vs $29.9M YoY, operating margin not applicable with operating expenses $54.9M
- Dabogratinib IR NMIBC largest R&D program, $7.3M vs $1.8M YoY; TYRA-200 ICC lowest, $(0.1)M vs $0.0M
- Cash, equivalents and marketable securities $700.5M at September 30, 2026, financing proceeds $376.2M
- Runway through 2030; expected higher R&D spending, clinical-trial costs and operating losses, with tariffs and geopolitical risks as headwinds
AI summary of the TYRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for reported financial results and management commentary
Item EX-99.1: Item EX-99.1
- Initial SURF302 results showed 79% ORR and 64% BOR CR at 60 mg QD across 14 patients
- Single-lesion patients delivered 100% ORR and 75% BOR CR, supporting planned Phase 3 adjuvant development in 2027
Item 8.01: Other Events
- $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants
- Underwritten offering priced at $22.03 per share, with underwriters purchasing at $20.7082
Item EX-99.1: Item EX-99.1
- $400.0M gross equity offering priced at $22.03 per share, materially strengthening Tyra’s funding position
- 9,079,000 shares plus pre-funded warrants for 9,078,529 shares, creating substantial potential dilution
Item 8.01: Other Events
- SURF302 supports selective FGFR3 inhibition, with 60 mg QD identified as the potential registrational adjuvant dose
- 60 mg cohort: 79% ORR and 64% best overall CR among 14 evaluable participants
AI summaries of TYRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TYRA
Don't miss the next TYRA filing
- Alerts as it files. A push when TYRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TYRA, by share count.
- Ask anything. An AI agent that reads every TYRA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Buy | Sep 15, 2026 | 9,078,529 | $22.03 |
| Harris Todd | A | Sep 15, 2026 | 864 | $9.13 |
| Fuhrman Alan | A | Sep 15, 2026 | 951 | $9.13 |
| Rueb Yuliya | A | Sep 15, 2026 | 2,925 | $9.13 |
| Verjee Rehan | Buy | Sep 9, 2026 | 971.894 | $20.58 |
| Rothenberg Stephen Michael | A | May 28, 2026 | 13,160 | - |
| MORE ROBERT J | A | May 28, 2026 | 13,160 | - |
| Gulfo Adele M. | A | May 28, 2026 | 13,160 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$79.9M | -$104.2M | -$132.8M |
| Net Income | -$69.1M | -$86.5M | -$119.9M |
| Balance Sheet | |||
| Total Assets | $225.9M | $363.6M | $282.6M |
| Equity | - | $343.2M | $259.2M |
| ROE | - | -25.2% | -46.3% |
| Per Share | |||
| EPS | $-1.62 | $-1.51 | $-2.01 |
| Cash Flow | |||
| Operating CF | -$50.1M | -$69.8M | -$95.1M |
| CapEx | $770K | $664K | $141K |
Source: XBRL data in Tyra Biosciences, Inc. (TYRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TYRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $304.9M |
| Q2 2026 | 26 | $708.4M |
| Q1 2026 | 26 | $603.8M |
| Q4 2025 | 22 | $153.9M |
| Q3 2025 | 23 | $80.9M |
| Q2 2025 | 23 | $58.1M |
| Q1 2025 | 19 | $44.4M |
| Q4 2024 | 16 | $77.5M |
- Franklin Resources+648.2K (+337%)
- BlackRock+327.4K (+11%)
- Vanguard Capital Management LLC+259.7K (+17%)
- Dimensional Fund Advisors+111.9K (+52%)
- AQR Capital Management+64.0K (+214%)
- T. Rowe Price Group−203.0K (-7%)
- Millennium Management−150.2K (-85%)
- State Street Corp−142.9K (-7%)
- Citadel Advisors LLC−141.6K (-51%)
- Morgan Stanley−93.4K (-31%)
- U.S. Bancorp+59
- FMR LLC (Fidelity)−8.92M
- Ameriprise Financial−16.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TYRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| SC 13G | Sep 21, 2026 | - | - | |
| 4 | Sep 17, 2026 | - | - | - |
| SC 13G | Sep 17, 2026 | - | - | |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 30, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TYRA SEC filings: frequently asked questions
Are TYRA insiders buying or selling?
In the last 90 days, Tyra Biosciences, Inc. (TYRA) officers, directors and 10% owners reported 1 open-market purchase worth $20,000 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TYRA stock?
As of September 30, 2026, the largest Tyra Biosciences, Inc. (TYRA) holders among the 13F filers tracked by SignalX were BlackRock ($73.5 million), T. Rowe Price Group ($56.4 million), State Street Corp ($43.7 million), Vanguard Capital Management LLC ($38.7 million), Franklin Resources ($18.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TYRA report in its latest 8-K?
Tyra Biosciences, Inc. (TYRA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026.
What are the latest TYRA SEC filings?
Tyra Biosciences, Inc. (TYRA) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 17, 2026.
What is TYRA's SEC CIK number?
Tyra Biosciences, Inc. (TYRA)'s SEC Central Index Key (CIK) is 1863127. EDGAR lists every TYRA filing under that number.
Ask anything about TYRA
The research agent reads TYRA's filings, financials, insider trades and 13F holders, then answers with sources.